This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree

Summary

RA Capital has participated in four biotech financings in September, while Janus Henderson leads in biotech reverse merger deal backing for the year. The article provides routine market commentary without specific details on Novartis' performance drivers.